Moonlight AI raised $3.3 million to expand its diagnostic image-analysis software that links routine imaging—such as genomic biomarkers and disease signatures from blood and cytology smears—to clinical programs in hematologic and solid cancers. The funding was led by Lotus One Investment and included VP Venture Partners, Medin Fund, N&V Capital, and QAI Ventures. Moonlight said it will use the round to grow its library of whole-slide cytopathology images paired with genomic data through collaborations with hospitals and laboratories. The company plans to add employees and advance diagnostic programs in myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia. Its approach targets cytology and imaging workflows to extract molecular signals without relying on more invasive sampling. Market impact is tied to the speed of biomarker discovery and the potential to scale diagnostic decision-making using existing pathology infrastructure.